For the Sham BMMSCs, the enhancement was not as substantial as for the OVX BMMSCs, with a 3.5 times enhancement of the Sham OP compared with the Sham OM at the Runx2 promoter region and a 2.3 times enhancement at the OC promoter region (Figures 4a and c). The gene discussed is RUNX2; the disease is ocular melanoma.